Literature DB >> 31161211

Prognostic significance of serum cholinesterase in patients with acute decompensated heart failure: a prospective comparative study with other nutritional indices.

Masahiro Seo1, Takahisa Yamada1, Shunsuke Tamaki1, Takashi Morita1, Yoshio Furukawa1, Yusuke Iwasaki1, Masato Kawasaki1, Atsushi Kikuchi1, Tsutomu Kawai1, Makoto Abe1, Jun Nakamura1, Kyoko Yamamoto1, Kiyomi Kayama1, Masatsugu Kawahira1, Kazuya Tanabe1, Takanari Kimura1, Kunpei Ueda1, Daisuke Sakamoto1, Yasushi Sakata2, Masatake Fukunami1.   

Abstract

BACKGROUND: Nutritional status is associated with poor outcomes in patients with heart failure. Serum cholinesterase (CHE) concentration, a marker of malnutrition, was reported to be a prognostic factor in patients with chronic heart failure. The geriatric nutritional risk index (GNRI), the controlling nutritional status (CONUT) score, and the prognostic nutritional index (PNI) are established objective nutritional indices.
OBJECTIVE: The aim of this study was to clarify the prognostic significance of CHE concentration and to compare it with other well-established objective nutritional indices in patients with acute decompensated heart failure (ADHF).
METHODS: We prospectively enrolled 371 consecutive patients admitted for ADHF with survival discharge. Laboratory data including CHE and the objective nutritional indices were obtained at discharge. The primary endpoint of this study was all-cause mortality.
RESULTS: During a mean ± SD follow-up period of 2.5 ± 1.4 y, 112 patients died. CHE concentration was significantly associated with all-cause mortality independently of GNRI, CONUT score, or PNI, after adjustment for major confounders including other nutritional indices, such as age, sex, systolic blood pressure, BMI, left ventricular ejection fraction, history of hypertension, diabetes mellitus, dyslipidemia, prior heart failure hospitalization, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, β-blocker use, statin use, hemoglobin, sodium, blood urea nitrogen, albumin, C-reactive protein, and brain natriuretic peptide concentrations via multivariable Cox analysis. Kaplan-Meier analysis revealed that the risk of all-cause mortality significantly increased in accordance with CHE stratum [lowest tertile: 53%, adjusted HR: 6.92; 95% CI: 3.87, 12.36, compared with middle tertile: 28%, adjusted HR: 2.72; 95% CI: 1.45, 5.11, compared with highest tertile: 11%, adjusted HR: 1.0 (reference), P < 0.0001]. CHE showed the best area under the curve value (0.745) for the prediction of all-cause mortality compared with the other objective nutritional indices. Net reclassification improvement afforded by adding CHE to the fully adjusted multivariable model was statistically significant for all-cause mortality (0.330; 95% CI: 0.112, 0.549, P = 0.0030).
CONCLUSION: CHE is a simple, strong prognostic marker for the prediction of all-cause mortality in patients with ADHF. © American Society for Nutrition 2019.

Entities:  

Keywords:  acute decompensated heart failure; cardiac cachexia; controlling nutritional status score; geriatric nutritional risk index; nutritional indices; prognostic nutritional index; serum cholinesterase

Year:  2019        PMID: 31161211     DOI: 10.1093/ajcn/nqz103

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  7 in total

1.  Prognostic value of nutritional parameters in systolic heart failure with renal dysfunction.

Authors:  Takahiro Doi; Takahiro Noto; Tomohiro Mita; Daigo Nagahara; Satoshi Yuda; Akiyoshi Hashimoto; Tomoaki Nakata; Kenichi Nakajima
Journal:  PLoS One       Date:  2022-05-19       Impact factor: 3.752

2.  Prognostic Significance of Serum Cholinesterase Level in Patients With Acute Decompensated Heart Failure With Preserved Ejection Fraction: Insights From the PURSUIT-HFpEF Registry.

Authors:  Masahiro Seo; Takahisa Yamada; Shunsuke Tamaki; Shungo Hikoso; Yoshio Yasumura; Yoshiharu Higuchi; Yusuke Nakagawa; Masaaki Uematsu; Haruhiko Abe; Hisakazu Fuji; Toshiaki Mano; Daisaku Nakatani; Masatake Fukunami; Yasushi Sakata
Journal:  J Am Heart Assoc       Date:  2019-12-18       Impact factor: 5.501

3.  Incremental prognostic value of cardiac metaiodobenzylguanidine imaging over the co-morbid burden in acute decompensated heart failure.

Authors:  Kiyomi Kayama; Takahisa Yamada; Shunsuke Tamaki; Tetsuya Watanabe; Takashi Morita; Yoshio Furukawa; Masato Kawasaki; Atsushi Kikuchi; Tsutomu Kawai; Masahiro Seo; Jun Nakamura; Masatsugu Kawahira; Masatake Fukunami
Journal:  ESC Heart Fail       Date:  2021-01-12

4.  Prognostic value of impaired hepato-renal function and liver fibrosis in patients admitted for acute heart failure.

Authors:  Masatsugu Kawahira; Shunsuke Tamaki; Takahisa Yamada; Tetsuya Watanabe; Takashi Morita; Yoshio Furukawa; Masato Kawasaki; Atsushi Kikuchi; Tsutomu Kawai; Masahiro Seo; Jun Nakamura; Kiyomi Kayama; Takanari Kimura; Kunpei Ueda; Daisuke Sakamoto; Takehiro Kogame; Shota Ito; Yongchol Chang; Masatake Fukunami
Journal:  ESC Heart Fail       Date:  2021-01-20

5.  The Role of Deep Learning-Based Echocardiography in the Diagnosis and Evaluation of the Effects of Routine Anti-Heart-Failure Western Medicines in Elderly Patients with Acute Left Heart Failure.

Authors:  Jinyou Chen; Yue Gao
Journal:  J Healthc Eng       Date:  2021-08-09       Impact factor: 2.682

6.  Admission serum cholinesterase concentration for prediction of in-hospital mortality in very elderly patients with acute ischemic stroke: a retrospective study.

Authors:  Mingquan Li; Yan Chen; Yanli Zhang; Xiaoyun Liu; Tiantian Xie; Jingjing Yin; Liumin Wang; Shucheng Gang; Jinjin Chen; Ling Liu; Fang Yang; Tongchao Geng
Journal:  Aging Clin Exp Res       Date:  2020-02-18       Impact factor: 3.636

7.  Serum Cholinesterases, a Novel Marker of Clinical Activity in Inflammatory Bowel Disease: A Retrospective Case-Control Study.

Authors:  Xiaona Shao; Lei Yang; Keyue Hu; Ruiwei Shen; Qunqun Ye; Xiaogang Yuan; Qiang Zhao; Jianwei Shen
Journal:  Mediators Inflamm       Date:  2020-07-14       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.